Aptevo Therapeutics (NASDAQ: APVO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.150 | -1.550 | -0.4000 | ||||
REV | 3.750M | 3.114M | -636.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Aptevo Therapeutics (NASDAQ: APVO) through any online brokerage.
Other companies in Aptevo Therapeutics’s space includes: Panbela Therapeutics (NASDAQ:PBLA), Biocept (NASDAQ:BIOC), Acurx Pharmaceuticals (NASDAQ:ACXP), Cellectar Biosciences (NASDAQ:CLRB) and Addex Therapeutics (NASDAQ:ADXN).
The latest price target for Aptevo Therapeutics (NASDAQ: APVO) was reported by Piper Sandler on Friday, May 13, 2022. The analyst firm set a price target for 20.00 expecting APVO to rise to within 12 months (a possible 339.56% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Aptevo Therapeutics (NASDAQ: APVO) is $4.55 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for Aptevo Therapeutics.
Aptevo Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Aptevo Therapeutics.
Aptevo Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.